How Stressed Beta Cells Trigger the Immune Attack in Type 1 Diabetes

Type 1 diabetes develops when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Researchers have long searched for what tips this balance toward autoimmunity. New evidence points to two specific chemical modifications that happen to beta cell proteins when cells are under stress: citrullination and deamidation.

These modifications are not unique to diabetes—they occur in other autoimmune diseases too. But in Type 1 diabetes, they appear to play a central role in making beta cells look like invaders to the immune system. When beta cells face inflammatory stress or problems in the endoplasmic reticulum (the cell's protein-making center), they activate specialized enzymes that chemically alter their own proteins. These altered proteins become what researchers call 'neoepitopes'—essentially new targets that immune cells have never been trained to recognize.

While citrullination and deamidation are chemically similar, they follow different patterns as Type 1 diabetes develops. Citrullination appears to be an earlier response—something stressed beta cells do relatively quickly as part of their stress response. Deamidation, by contrast, emerges later and is more closely tied to ongoing inflammation in the pancreas.

This timing matters. It suggests that citrullination might be an early warning sign of beta cell trouble, while deamidation becomes more prominent as the disease progresses. Both modifications alter the electrical charge and shape of proteins, changing how tightly they fit into the grooves of HLA molecules—the structures on cell surfaces that present protein fragments to immune cells. A better fit can mean stronger immune activation against these modified proteins.

The human immune system normally learns during childhood which proteins belong to the body and which are foreign invaders. This education happens in the thymus, a gland where developing T cells are trained to attack only threats. But the thymus appears to have limited access to these chemically modified beta cell proteins.

Studies suggest that the enzymes responsible for citrullination and deamidation are expressed at low levels in the thymus. This means developing immune cells never get properly 'taught' to recognize and tolerate these modified proteins. As a result, T cells that can attack citrullinated or deamidated beta cell proteins may escape into the body without being weeded out. Once they encounter these modified proteins in the pancreas, they attack.

Current evidence suggests that citrullination and deamidation drive the spread of autoimmunity rather than spark it in the first place. Immune responses against these modified proteins increase as Type 1 diabetes progresses, pointing to a role in epitope spreading—the process where the immune attack gradually expands to target more and more beta cell proteins.

This distinction is important. It means these modifications may not be the root cause of Type 1 diabetes, but rather a mechanism that amplifies and perpetuates it. Research in both mice and humans supports this pattern, showing that modified beta cell proteins are increasingly recognized by immune cells as disease advances.

Understanding how citrullination and deamidation fuel autoimmunity opens potential new avenues for intervention. If researchers can develop ways to block these enzymes, reduce their activity, or prevent the immune system from attacking the modified proteins they create, it might be possible to slow disease progression.

The distinct timelines of these two modifications also suggest opportunities. Earlier intervention targeting citrullination might prevent the escalation to deamidation and advanced disease. This research represents one of many efforts to move beyond managing Type 1 diabetes to actually slowing or preventing it.

Source: Immunological reviews. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.